RT Journal Article
SR Electronic
T1 Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr-2017-221801
DO 10.1136/bcr-2017-221801
VO 2018
A1 Sandra D Algaze
A1 Wungki Park
A1 Thomas J Harrington
A1 Raja Mudad
YR 2018
UL http://casereports.bmj.com/content/2018/bcr-2017-221801.abstract
AB We describe a rare case of severe autoimmune haemolytic anaemia (AIHA) in the setting of underlying chronic lymphocytic leukaemia receiving intravenous immunoglobulin, history of warm IgG autoantibody and treatment with nivolumab for advanced non-small cell lung cancer. In this report, we describe AIHA as a potential serious immune-related adverse event from immune checkpoint inhibitors, discuss other potential contributing factors and review previously described cases of AIHA in patients receiving programmed death 1 (PD-1) inhibitors. In the era of immunotherapy, we hope to add literature to raise awareness of potential immune-related sequelae such as AIHA. We aim to highlight the importance of close monitoring for prompt identification and management of potentially fatal AIHA and immune-related adverse events of PD-1 inhibitors by holding immunotherapy and treating with high-dose steroids, particularly in subgroups which may be at increased risk.